Selling, General, and Administrative Costs: AstraZeneca PLC vs Galapagos NV

A Tale of Two Companies: AstraZeneca PLC vs. Galapagos NV

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. Over the past decade, AstraZeneca PLC and Galapagos NV have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. AstraZeneca, a global leader, has seen its SG&A costs rise by approximately 35% from 2014 to 2023, peaking in 2022. This increase reflects its expansive global operations and strategic investments. In contrast, Galapagos NV, a smaller biotech firm, experienced a staggering 2,500% increase in SG&A expenses over the same period, highlighting its aggressive growth strategy and market expansion efforts. While AstraZeneca's expenses are significantly higher, Galapagos's rapid growth trajectory is noteworthy. These trends underscore the diverse strategies employed by pharmaceutical companies to navigate the competitive landscape and drive innovation.